A spoonful of sugar helps the proteinuria go down?*

Peter Topham1,2, Jonathan Barratt1,2 and John Feehally1,2

1Department of Infection, Immunity and Inflammation, University of Leicester and John Walls Renal Unit, Leicester, UK and 2University Hospitals of Leicester NHS Trust, Leicester, UK

Keywords: proteinuria; glomerulonephritis; glycosylation; sialic acid; HIBM

Summary

This paper describes kidney defects in knock-in mice homozygous for the M712T mutation in the gene encoding for uridine diphospho-N-acetylgalactosamine 2-epimerase/N-acetylmannosamine kinase (GNE/MNK). In humans, this genetic defect causes hereditary inclusion body myopathy (HIBM), an autosomal recessive neuromuscular disorder characterized by adult onset, slowly progressive muscle weakness and atrophy. GNE/MNK is ubiquitously expressed and catalyses the first two rate-limiting steps in the biosynthesis of 5-N-acetylneuraminic acid (sialic acid). HIBM is thought to result from hyposialylation of muscle glycopolymers. The aim of the study was to generate a model of HIBM, in which the hypothesis that supplementation with free sialic acid could ameliorate the muscle disease could be tested. Unexpectedly, M712T homozygotes did not survive beyond Day 3 post-partum. At this point no myopathic features were detectable, but there was evidence of significant glomerular pathology [(haematuria, proteinuria, podocyte foot process effacement and splitting of the glomerular basement membrane (GBM)]. Dietary supplementation with the sialic acid precursor, N-acetylmannosamine (MannNAc) improved survival of homozygous pups and renal histology. Interestingly, patients with HIBM do not develop renal disease.

This study raises three important questions: is the renal disease in these mice related to a defect in sialylation; why is the renal phenotype in mice and humans so different; and can sialic acid supplementation be used to treat human proteinuric disease?

Review of the field

In order to maintain a constant internal milieu, the glomeruli are required to generate 180 L of ultrafiltrate per day. In health, this ultrafiltrate is remarkably free of macromolecular contamination. This permselective function is dependent on the integrity of the glomerular filtration barrier that comprises fenestrated endothelial cells, the glomerular basement membrane (GBM) and podocytes. All three components of the filtration barrier are richly decorated with an anionic glycocalyx comprising proteoglycans, glycosaminoglycans and sialoglycoproteins. There is substantial experimental evidence indicating that the charge characteristics of the filtration barrier are critical determinants of the barrier function of the glomerulus. Removal of glomerular sialic acid by infusion of sialidase and neutralization of surface sialic acid using polycations such as protamine sulphate, results in proteinuria and podocyte foot process effacement [1,2]. Puromycin aminonucleoside administration results in foot process effacement and reduction of glomerular sialic acid content [3,4]. Interestingly, this is specifically due to a reduction in sialic acid, rather than loss of sialoglycoproteins [4]. Furthermore, the infusion of sialic acid-rich alpha-1-acid glycoprotein in this model prevents proteinuria and podocyte foot process effacement, presumably through sialylation of critical glomerular proteins [5]. Human proteinuric renal diseases such as minimal change disease are also associated with reduced glomerular sialylation [6], and in some studies with reduced red blood cell sialic acid content, suggesting a more widespread deficiency of sialylation [7].

Podocalyxin, the major glomerular sialoglycoprotein [8], is found on glomerular endothelial cells and on the apical surface of podocytes, where it interacts with the ezrin/NHERF2/actin protein complex and links the actin cytoskeleton to the apical membrane [9]. Desialylation of podocalyxin or neutralization with polycation causes this protein complex to break down, and results in foot process effacement and proteinuria [9]. Mice with a targeted deletion of podocalyxin die within 24 h of birth, with profound abnormalities of glomerular development (absence of podocyte processes and slit-diaphragms), and extrarenal manifestations such as omphaloceles and hernias [10]. Interestingly, in contrast to mice with the M712T mutation,
podocalyxin knock-out mice do not have abnormalities of the GBM. This suggests that reduced sialylation of other proteins may account for the GBM changes. Podocytes are linked to the GBM through a number of sialylated anchoring molecules such as α1β3 integrin and α/β-dystroglycans [11,12]. These molecules facilitate crosstalk between the GBM and the podocytes and determine podocyte structure and possibly also the composition of the GBM. Altered sialylation of these molecules or other anchoring proteins may account for the observed GBM changes, through altered signalling and dysregulation of GBM synthesis.

It is possible that additional factors contributed to the M712T phenotype, since GNE/MNK also enhances the activity of the sialyltransferases, GM3 synthase and GD3 synthase, thereby increasing synthesis of the gangliosides GM3 and GD3 [13]. These are expressed in podocytes, contribute to the charge characteristics of the filtration barrier and are reduced in response to puromycin aminonucleoside and diabetes-induced injury [14–16].

Taken together however, these data highlight the importance of sialic acid to the normal structure and function of the glomerular filtration barrier, and indicate that the renal abnormalities observed in this paper were probably due to impaired sialic acid synthesis.

Given the findings in this mouse model, the absence of renal disease in patients with HIBM needs to be explained. The inter-species differences in sialic acid utilization (Neu5Gc in mice and Neu5Ac in humans) and protein glycosylation patterns may provide some insight but are unlikely to be the whole explanation [17]. There may be some specific consequence of the way this model was generated, since in a separate study, mice with a targeted deletion of GNE/MNK rescued with a GNE transgene expressing the V572L mutation (found in Japanese patients with HIBM) developed myopathic features similar to that seen with HIBM, but had no evidence of disease of other internal organs, although the kidneys were not examined in detail [18]. The M712T and V572L mutations result in similar phenotypes in humans, therefore, the significant disparity in mouse phenotypes raises concerns that factors other than sialylation may be involved in the M712T model.

How could this affect my clinical work?

Perhaps the most exciting aspect of this paper is the observation that dietary supplementation with MannNAc, a cell-permeable precursor of sialic acid, extended survival of M712T homozygous mice, improved the renal histology, increased sialylation of podocalyxin and increased both GNE/MNK protein expression and Gne epimerase activities. This raises the question of whether similar strategies could have a therapeutic use in patients with proteinuric disease. There is some experimental precedent for therapeutically restoring the charge characteristics of the glomerular filtration barrier in humans. Administration of the anionic glycosaminoglycan, sulodexide, has been shown to reduce albumin excretion in patients with both micro- and macroalbuminuric diabetic nephropathy [19]. Although the mechanism of this effect is unknown, it is postulated that it is at least in part mediated by correction of the glomerular charge defect.

If the sialylation defect observed in experimental models of proteinuric disease and human proteinuric disease is the result of acquired defects in the sialic acid synthetic pathway, supplementation with MannNAc may be therapeutically beneficial and this hypothesis warrants further investigation.

Take home message

Sialic acid supplementation may be therapeutically helpful in proteinuric glomerular diseases characterized by hypsialylation.

Conflict of interest statement. None declared.

References


Downloaded from https://academic.oup.com/ndt/article-abstract/23/3/813/1832071 by guest on 19 March 2019


Received for publication: 12.9.07
Accepted in revised form: 14.9.07